Skip to Primary Navigation

Skip to main content

Major generic drug firms pay big fine, divest key lines in agreement with DOJ

Image of a pharmacist stocking shelves with bottles of pills.
Photo: Joe Raedle/Getty Images

Julie DiMauro

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

DOJ resolves criminal antitrust charges against big pharma, with a novel twist as businesses agree to divest key product lines.

In the first US Department of Justice (DOJ) resolution to require pharmaceutical companies to divest drug-product lines, the agency announced on Monday two deferred prosecution agreements resolving criminal antitrust charges against Teva Pharmaceuticals USA, Inc. and Glenmark Pharmaceuticals Inc., USA.

The two companies were charged in 2020 with conspiring to

Teva

, , , ,